• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Cullinan Therapeutics Inc.

    1/6/25 4:22:42 PM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CGEM alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001838061
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    CULLINAN THERAPEUTICS, INC.
    SEC File Number
    001-39856
    Address of Issuer
    One Main Street, Suite 1350
    Cambridge
    MASSACHUSETTS
    02142
    Phone
    6174104650
    Name of Person for Whose Account the Securities are To Be Sold
    JENNIFER MICHAELSON
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    COMMON
    Morgan Stanley Smith Barney LLC Executive Financial Services
    1 New York Plaza
    8th Floor
    New York � NY � 10004
    8000101440.005822759301/06/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common12/16/2019Restricted Stock UnitsIssuerCheckbox not checked452312/16/2019N/A
    Common01/06/2025Exercise of Stock OptionsIssuerCheckbox not checked347701/06/2025Cash

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    JENNIFER MICHAELSON
    One Main Street, Suite 1350
    Cambridge � MA � 02142
    Common12/18/2024469353547.13
    JENNIFER MICHAELSON
    One Main Street, Suite 1350
    Cambridge � MA � 02142
    Common12/12/2024348943682.28
    10b5-1 Sales for JENNIFER MICHAELSON
    One Main Street, Suite 1350
    Cambridge � MA � 02142
    COMMON11/05/20248000125102.80

    144: Remarks and Signature

    Remarks
    The securities to be sold were acquired upon the vesting of restricted stock units during the period of 12/16/2023 through 12/17/2023 The securities to be sold will be received upon the exercise of stock options over the next three months. The dates of acquisition and payment will be the dates of exercise/sale.
    Date of Notice
    01/06/2025
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    01/05/2024

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Jennifer Michaelson

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $CGEM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CGEM

    DatePrice TargetRatingAnalyst
    8/21/2025$24.00Buy
    H.C. Wainwright
    6/11/2025$22.00Buy
    Stifel
    10/24/2024$30.00Buy
    UBS
    5/1/2024$40.00Buy
    Stifel
    4/15/2024Outperform
    William Blair
    2/15/2024$30.00Outperform
    Wedbush
    6/15/2023Outperform
    TD Cowen
    11/21/2022$20.00Buy
    BTIG Research
    More analyst ratings

    $CGEM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Lynx1 Capital Management Lp bought $1,391,686 worth of shares (165,667 units at $8.40) (SEC Form 4)

    4 - Cullinan Therapeutics, Inc. (0001789972) (Issuer)

    10/30/25 5:13:32 PM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Lynx1 Capital Management Lp bought $114,048 worth of shares (15,032 units at $7.59) and bought $1,989,864 worth of shares (233,717 units at $8.51) (SEC Form 4)

    4 - Cullinan Therapeutics, Inc. (0001789972) (Issuer)

    10/21/25 7:00:03 PM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Lynx1 Capital Management Lp bought $3,593,698 worth of shares (556,300 units at $6.46) and bought $6,233,243 worth of shares (903,341 units at $6.90) (SEC Form 4)

    4 - Cullinan Therapeutics, Inc. (0001789972) (Issuer)

    10/10/25 6:58:38 PM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CGEM
    SEC Filings

    View All

    Cullinan Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Cullinan Therapeutics, Inc. (0001789972) (Filer)

    12/8/25 10:34:15 AM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cullinan Therapeutics Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement

    8-K - Cullinan Therapeutics, Inc. (0001789972) (Filer)

    11/21/25 4:30:26 PM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Cullinan Therapeutics Inc.

    SCHEDULE 13G/A - Cullinan Therapeutics, Inc. (0001789972) (Subject)

    11/14/25 4:03:50 PM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CGEM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation at the 67th ASH Meeting

    CLN-049 monotherapy demonstrates promising efficacy, including multiple complete responses and encouraging response durability, in a heavily pretreated all-comer population of patients with R/R AML 31% CR/CRh rate observed at the highest target dose tested to date; initial dose escalation results in 45 patients demonstrate a favorable safety profile across all doses assessed CLN-049 recently granted Fast Track designation by the U.S. FDA Company to host in-person event on Monday, December 8, at 8:00 p.m. ET CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-cl

    12/8/25 10:31:00 AM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cullinan Therapeutics Receives FDA Fast Track Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia

    Promising efficacy and favorable safety data from the Phase 1 study in heavily pre-treated patients show potential of CLN-049 to address a broad population of AML patients CAMBRIDGE, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CLN-049 for the treatment of relapsed/refractory (R/R) acute myeloid leukemia (AML). Data from the Phase 1 clinical trial of CLN-049 will be presented at the upcoming 67th America

    12/1/25 7:00:00 AM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics Initiate Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Zipalertinib for Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

    PRINCETON, N.J. and TOKYO and CAMBRIDGE, Mass., Nov. 20, 2025 /PRNewswire/ -- Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (NASDAQ:CGEM) today announced the companies have initiated the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval of zipalertinib, an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion (ex20ins) mutations who have previously received platinum-based systemic chemotherapy.

    11/20/25 7:00:00 AM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CGEM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on Cullinan Therapeutics with a new price target

    H.C. Wainwright resumed coverage of Cullinan Therapeutics with a rating of Buy and set a new price target of $24.00

    8/21/25 8:17:52 AM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Stifel resumed coverage on Cullinan Therapeutics with a new price target

    Stifel resumed coverage of Cullinan Therapeutics with a rating of Buy and set a new price target of $22.00

    6/11/25 8:09:08 AM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    UBS initiated coverage on Cullinan Therapeutics with a new price target

    UBS initiated coverage of Cullinan Therapeutics with a rating of Buy and set a new price target of $30.00

    10/24/24 6:18:20 AM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CGEM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Scientific Officer Michaelson Jennifer sold $49,200 worth of shares (4,000 units at $12.30), decreasing direct ownership by 3% to 138,004 units (SEC Form 4)

    4 - Cullinan Therapeutics, Inc. (0001789972) (Issuer)

    11/25/25 5:00:03 PM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Lynx1 Capital Management Lp bought $1,391,686 worth of shares (165,667 units at $8.40) (SEC Form 4)

    4 - Cullinan Therapeutics, Inc. (0001789972) (Issuer)

    10/30/25 5:13:32 PM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Lynx1 Capital Management Lp bought $114,048 worth of shares (15,032 units at $7.59) and bought $1,989,864 worth of shares (233,717 units at $8.51) (SEC Form 4)

    4 - Cullinan Therapeutics, Inc. (0001789972) (Issuer)

    10/21/25 7:00:03 PM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CGEM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Cullinan Therapeutics Inc.

    SC 13G/A - Cullinan Therapeutics, Inc. (0001789972) (Subject)

    11/14/24 5:05:22 PM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cullinan Therapeutics Inc.

    SC 13G/A - Cullinan Therapeutics, Inc. (0001789972) (Subject)

    11/14/24 4:24:39 PM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cullinan Therapeutics Inc.

    SC 13G/A - Cullinan Therapeutics, Inc. (0001789972) (Subject)

    11/12/24 2:23:54 PM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CGEM
    Financials

    Live finance-specific insights

    View All

    Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

    CLN-978 program now actively enrolling across Phase 1 studies in systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and Sjögren's disease BCMA-directed bispecific T cell engager velinotamig in-licensed from Genrix Bio Zipalertinib REZILIENT1 pivotal results shared in oral presentation at ASCO 2025 and in Journal of Clinical Oncology; multiple new data sets across a range of disease settings to be shared at IASLC 2025 WCLC and ESMO Congress 2025 Company appoints Mittie Doyle, M.D., and Andrew Allen, M.D., Ph.D., to its Board of Directors CAMBRIDGE, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM, "Cullinan")), a biopharmaceutical company focu

    8/7/25 7:00:00 AM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific T Cell Engager, from Genrix Bio for Development in Autoimmune Diseases

    Advances Cullinan's leadership in T cell engager (TCE) development for autoimmune diseases with both a CD19 TCE and BCMA TCE in its pipeline Strengthens Cullinan portfolio of autoimmune programs with the opportunity to address a broader range of diseases while maintaining cash runway into 2028 Company to host conference call today at 4:30 pm ET CAMBRIDGE, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM, "Cullinan")), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that it has entered into an agreement with Genrix Bio for a global (ex-Greater China), all indication, exclusive license to velinotamig,

    6/4/25 4:02:00 PM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

    Company received approval from European Medicines Agency (EMA) for CLN-978; Phase 1 study in active, difficult-to-treat rheumatoid arthritis to initiate in Q2 2025 CLN-978 expands into Sjögren's disease; Phase 1 study in active, moderate to severe patients to initiate in the U.S. in Q2 2025 Zipalertinib REZILIENT1 results to be shared in oral presentation at 2025 ASCO Annual Meeting CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM, "Cullinan")), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today reported recent and anticipated business highlights and announced its financial results for the first

    5/8/25 7:00:00 AM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CGEM
    Leadership Updates

    Live Leadership Updates

    View All

    Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer

    CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced the appointment of Mary Kay Fenton as Chief Financial Officer, beginning April 29. "I am pleased to welcome Mary Kay to Cullinan Therapeutics as Chief Financial Officer. This is a pivotal time for Cullinan as we expand into autoimmune diseases and continue to advance our clinical-stage oncology portfolio," said Nadim Ahmed, Chief Executive Officer, Cullinan Therapeutics. "Mary Kay brings a wealth of expertise to our team with a successful track record marked by pivotal roles leading in a variety of fast

    4/29/24 7:00:00 AM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cullinan Oncology Announces the Appointment of David P. Ryan, M.D. to its Board of Directors

    CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (NASDAQ:CGEM) ("Cullinan Oncology"), a biopharmaceutical company focused on modality-agnostic targeted oncology for patients with cancer, today announced that David P. Ryan, M.D. has been appointed to the company's Board of Directors ("Board"). Dr. Ryan brings over 20 years of oncology experience and joins Cullinan Oncology from Massachusetts General Hospital ("MGH") Cancer Center where he holds the position of Clinical Director and has been the Chief of the MGH Cancer Center since 2012.   Dr. Ryan holds a doctoral degree in medicine from Columbia College of Physicians and Surgeons. Following the completion of his

    11/2/22 8:00:00 AM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cullinan Oncology Announces Appointment of Jacquelyn Sumer as Chief Legal Officer

    CAMBRIDGE, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (NASDAQ:CGEM) ("Cullinan Oncology"), a biopharmaceutical company focused on developing a diversified pipeline of targeted therapeutic candidates across multiple modalities for patients with cancer, today announced that Jacquelyn (Jackie) Sumer, J.D., will join the company as Chief Legal Officer. Jackie brings with her nearly two decades of legal and strategic leadership experience, with proven skills in navigating legal and compliance issues through clinical development and commercialization of cancer therapies. "The appointment of Jackie as Chief Legal Officer brings her exceptional expertise and legal guidance a

    8/15/22 4:57:42 PM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care